Carlo Montagner
Vorstandsvorsitzender bei Specialised Therapeutics Australia Pty Ltd.
Profil
Carlo Montagner is the founder and Chief Executive Officer of Specialised Therapeutics Asia Pte Ltd.
founded in 2008.
He is currently the Chief Executive Officer of Specialised Therapeutics Australia Pty Ltd.
and a Director at Aadi Subsidiary, Inc. He is also a Member of the Australian Institute of Co. Directors since 1998.
Mr. Montagner has a graduate degree from RMIT University and an undergraduate degree from LaTrobe University.
Aktive Positionen von Carlo Montagner
| Unternehmen | Position | Beginn |
|---|---|---|
Australian Institute of Co. Directors
 Australian Institute of Co. Directors Miscellaneous Commercial ServicesCommercial Services Australian Institute of Co. Directors is a non-profit organization that provides leadership on director issues. It offers governance education, director development, and advocacy. The organization was founded in January 1, 1990 and is headquartered in Sydney, Australia. | Corporate Officer/Principal | 03.01.2011 |
| Specialised Therapeutics Australia Pty Ltd. | Vorstandsvorsitzender | - |
Aadi Subsidiary, Inc.
 Aadi Subsidiary, Inc. BiotechnologyHealth Technology Aadi Subsidiary, Inc. engages in biopharmaceutical company. Its therapeutic programs include pulmonary arterial hypertension, pediatric solid tumors, solid tumors with mTOR activation and mitochondrial disease. The company was founded by Neil Desai and is headquartered in Pacific Palisades, CA. | Direktor/Vorstandsmitglied | - |
Specialised Therapeutics Asia Pte Ltd.
 Specialised Therapeutics Asia Pte Ltd. Medical SpecialtiesHealth Technology Specialised Therapeutics Asia Pte Ltd. is a Singaporean international biopharmaceutical company that provides healthcare solutions to patients in Southeast Asia, Australia, and New Zealand. Specialised Therapeutics Asia is based in Singapore, Singapore. The private company collaborates with leading pharmaceutical and diagnostic companies to bring innovative therapies to patients with a range of diseases. The company's therapeutic portfolio includes novel agents in oncology, haematology, neurology, ophthalmology, and supportive care. The company was founded in 2008 by Carlo Montagner and Bozena Zembrzuski, and Carlo Montagner has been the CEO since then. | Vorstandsvorsitzender | 01.01.2008 |
Ehemalige bekannte Positionen von Carlo Montagner
| Unternehmen | Position | Ende |
|---|---|---|
| THE SUSTAINABLE NUTRITION GROUP LTD | Direktor/Vorstandsmitglied | 22.11.2011 |
| OPTHEA LIMITED | Direktor/Vorstandsmitglied | 15.10.2011 |
Abraxis BioScience, Inc.
 Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | Corporate Officer/Principal | 30.03.2011 |
Abraxis BioScience, Inc. /Old/
 Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL | Corporate Officer/Principal | 15.11.2007 |
| American Bioscience, Inc. | Corporate Officer/Principal | 01.04.2006 |
Ausbildung von Carlo Montagner
| RMIT University | Graduate Degree |
| LaTrobe University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| OPTHEA LIMITED | Health Technology |
| Private Unternehmen | 10 |
|---|---|
| Bayer Schering Pharma AG | Health Technology |
| American Bioscience, Inc. | Health Technology |
The Sustainable Nutrition Group Pty Ltd.
 The Sustainable Nutrition Group Pty Ltd. Agricultural Commodities/MillingProcess Industries The Sustainable Nutrition Group Ltd. produces, manufactures, and distributes a range of hemp products in Australia. It is involved in hemp seed selection, farming, processing, and packaging, as well as distribution and sale of bulk and retail products. The company's products include hand sanitizers, hemp oils, hemp seeds, hemp protein powders, and hemp flour under the APH and Mt Elephant brands to retail, wholesale, and white label customers. The company was founded by James Hood and Tracie Rams dale in 1995 and is headquartered in Newtown, Australia. | Process Industries |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | Health Technology |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL | Health Technology |
Australian Institute of Co. Directors
Australian Institute of Co. Directors Miscellaneous Commercial ServicesCommercial Services Australian Institute of Co. Directors is a non-profit organization that provides leadership on director issues. It offers governance education, director development, and advocacy. The organization was founded in January 1, 1990 and is headquartered in Sydney, Australia. | Commercial Services |
| Sanofi-Aventis Japan | |
| Specialised Therapeutics Australia Pty Ltd. | |
Aadi Subsidiary, Inc.
Aadi Subsidiary, Inc. BiotechnologyHealth Technology Aadi Subsidiary, Inc. engages in biopharmaceutical company. Its therapeutic programs include pulmonary arterial hypertension, pediatric solid tumors, solid tumors with mTOR activation and mitochondrial disease. The company was founded by Neil Desai and is headquartered in Pacific Palisades, CA. | Health Technology |
Specialised Therapeutics Asia Pte Ltd.
Specialised Therapeutics Asia Pte Ltd. Medical SpecialtiesHealth Technology Specialised Therapeutics Asia Pte Ltd. is a Singaporean international biopharmaceutical company that provides healthcare solutions to patients in Southeast Asia, Australia, and New Zealand. Specialised Therapeutics Asia is based in Singapore, Singapore. The private company collaborates with leading pharmaceutical and diagnostic companies to bring innovative therapies to patients with a range of diseases. The company's therapeutic portfolio includes novel agents in oncology, haematology, neurology, ophthalmology, and supportive care. The company was founded in 2008 by Carlo Montagner and Bozena Zembrzuski, and Carlo Montagner has been the CEO since then. | Health Technology |
